microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production
Proprotein convertase subtilisin/kexin type 9 (PCSK9) affects cholesterol homeostasis by targeting hepatic LDL receptor (LDLR) for lysosomal degradation. Clinically, PCSK9 inhibitors effectively reduce LDL-cholesterol (LDL-C) levels and the incidence of cardiovascular events. Because microRNAs (miRs...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society for Clinical investigation
2020-12-01
|
Series: | JCI Insight |
Subjects: | |
Online Access: | https://doi.org/10.1172/jci.insight.143812 |